BC Innovations | Aug 27, 2015
Distillery Therapeutics

Therapeutics: CTLA-4 (CD152); LPS-responsive vesicle trafficking beach and anchor containing (LRBA)

Autoimmune disease INDICATION: Autoimmune disease In vitro and patient sample studies suggest inhibitors of lysosomal degradation could help treat patients with autoimmune diseases caused by LRBA deficiency. Positive responses of LRBA-deficient patients to the CTLA-4-Ig...
Items per page:
1 - 1 of 1